The Autistic Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Autistic Disorder Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Autistic Disorder Market.
Some of the key takeaways from the Autistic Disorder Pipeline Report:
Companies across the globe are diligently working toward developing novel Autistic Disorder treatment therapies with a considerable amount of success over the years.
Autistic Disorder companies working in the treatment market are Scioto Biosciences, Hoffmann-La Roche, Yamo Pharmaceutical, Jazz Pharmaceuticals, Axial Therapeutics, Eli Lilly and Company, AbbVie, and others, are developing therapies for the Autistic Disorder treatment
Emerging Autistic Disorder therapies in the different phases of clinical trials are- SB-121, RO6953958, L1-79, JZP541, AB-2004, Tasimelteon, Cariprazine, and others are expected to have a significant impact on the Autistic Disorder market in the coming years.
In March 2024, SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company dedicated to developing treatments for central nervous system disorders, has reported the enrollment of the initial patient in its clinical trial evaluating the effectiveness and safety of SCI-210 in treating children aged 5 to 18 with autism spectrum disorder (ASD).
In January 2024, IAMA Therapeutics has administered treatment to the initial participant in the Phase I clinical trial of IAMA-6, a small molecule therapeutic targeting autism spectrum disorder and epilepsy. This pioneering trial, which is randomized, placebo-controlled, and double-blind, will include single ascending dose and multiple ascending dose stages. It aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the impact of food on the oral delivery of IAMA-6 in healthy adult volunteers.
In November 2023, Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company with marketed products and a pipeline of development candidates, announced that the first participant was enrolled in an investigator-initiated Phase II study of TNX-1900 (intranasal potentiated oxytocin) for improving bone health in children with autism spectrum disorder (ASD), named the BOX study, at Massachusetts General Hospital (MGH).
In July 2023, Greater Cannabis Company, Inc., a publicly traded biopharmaceutical company pioneering development of next generation therapeutics announced that it had been granted final approval for its double blind, placebo controlled Phase II Clinical Trial for the treatment of Autism Spectrum Disorder (ASD) from the Israel Ministry of Health.
Autistic Disorder Overview
Autistic Disorder, commonly referred to as autism, is a neurodevelopmental disorder characterized by significant challenges in social interaction, communication, and restricted, repetitive behaviors and interests. Autism Spectrum Disorder (ASD) encompasses a range of conditions, including Autistic Disorder, Asperger’s Syndrome, and Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS). Here, the focus is on Autistic Disorder specifically.
Get a Free Sample PDF Report to know more about Autistic Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/autistic-disorder-pipeline-insight
Emerging Autistic Disorder Drugs Under Different Phases of Clinical Development Include:
SB-121: Scioto Biosciences
RO6953958: Hoffmann-La Roche
L1-79: Yamo Pharmaceutical
JZP541: Jazz Pharmaceuticals
AB-2004: Axial Therapeutics
Tasimelteon: Eli Lilly and Company
Cariprazine: AbbVie
Autistic Disorder Route of Administration
Autistic Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Autistic Disorder Molecule Type
Autistic Disorder Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Autistic Disorder Pipeline Therapeutics Assessment
Autistic Disorder Assessment by Product Type
Autistic Disorder By Stage and Product Type
Autistic Disorder Assessment by Route of Administration
Autistic Disorder By Stage and Route of Administration
Autistic Disorder Assessment by Molecule Type
Autistic Disorder by Stage and Molecule Type
DelveInsight’s Autistic Disorder Report covers around 25+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Autistic Disorder product details are provided in the report. Download the Autistic Disorder pipeline report to learn more about the emerging Autistic Disorder therapies
Some of the key companies in the Autistic Disorder Therapeutics Market include:
Key companies developing therapies for Autistic Disorder are – F. Hoffmann-La Roche Ltd, Curemark, LLC, Zynerba Pharmaceuticals, Inc, Q BioMed Inc., PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Axial Therapeutics, Novartis AG, STALICLA, and others.
Autistic Disorder Pipeline Analysis:
The Autistic Disorder pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Autistic Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Autistic Disorder Treatment.
Autistic Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Autistic Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Autistic Disorder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Autistic Disorder drugs and therapies
Autistic Disorder Pipeline Market Drivers
Increasing Prevalence of Autistic Disorder, government initiatives to increase the awareness for the disease are some of the important factors that are fueling the Autistic Disorder Market.
Autistic Disorder Pipeline Market Barriers
However, side-effects associated with the treatment of Autistic Disorder, a lack of knowledge about the types of treatment available and other factors are creating obstacles in the Autistic Disorder Market growth.
Scope of Autistic Disorder Pipeline Drug Insight
Coverage: Global
Key Autistic Disorder Companies: Scioto Biosciences, Hoffmann-La Roche, Yamo Pharmaceutical, Jazz Pharmaceuticals, Axial Therapeutics, Eli Lilly and Company, AbbVie, and others
Key Autistic Disorder Therapies: SB-121, RO6953958, L1-79, JZP541, AB-2004, Tasimelteon, Cariprazine, and others
Autistic Disorder Therapeutic Assessment: Autistic Disorder current marketed and Autistic Disorder emerging therapies
Autistic Disorder Market Dynamics: Autistic Disorder market drivers and Autistic Disorder market barriers
Request for Sample PDF Report for Autistic Disorder Pipeline Assessment and clinical trials
Table of Contents
1. Autistic Disorder Report Introduction
2. Autistic Disorder Executive Summary
3. Autistic Disorder Overview
4. Autistic Disorder- Analytical Perspective In-depth Commercial Assessment
5. Autistic Disorder Pipeline Therapeutics
6. Autistic Disorder Late Stage Products (Phase II/III)
7. Autistic Disorder Mid Stage Products (Phase II)
8. Autistic Disorder Early Stage Products (Phase I)
9. Autistic Disorder Preclinical Stage Products
10. Autistic Disorder Therapeutics Assessment
11. Autistic Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Autistic Disorder Key Companies
14. Autistic Disorder Key Products
15. Autistic Disorder Unmet Needs
16 . Autistic Disorder Market Drivers and Barriers
17. Autistic Disorder Future Perspectives and Conclusion
18. Autistic Disorder Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: 14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
